# US 12,005,125 B2 · Nanoparticles for use in photodynamic therapies and methods of making, evaluating and using the same > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,005,125 B2 - Document ID: US12005125B2 - Status: Granted - Kind: B2 - Application number: 17/228,332 - Filed: 2021-04-12 - Published: 2021-10-14 - Granted: 2024-06-11 - Earliest claimed: 2020-04-10 - Assignees: Mi2 Holdings LLC - Applicants: Mi2 Holdings LLC - Inventors: Andrew Hopkins; Thomas Hopkins - Web page: https://patentgrep.com/patent/US12005125B2 ## CPC - A61K 47/6935: {the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol} - A61K 41/0071: {PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines} - A61K 47/62: the modifying agent being a protein, peptide or polyamino acid - A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65) - B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery - B82Y 30/00: Nanotechnology for materials or surface science, e.g. nanocomposites - B82Y 40/00: Manufacture or treatment of nanostructures - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES ## Abstract A nanocomposition for use in treating cardiac, oncologic, bariatric, or dermatologic indications, conditions and diseases condition using phthalocyanine dye, such as IR700. A nanocomposition having IR700, an 8PEG nanoparticle and a RGD, or iRGD targeting agent. Administering a product comprising IR700 to a patient, whereby the IR700 is delivered to the target tissue, and found in only target tissue; and administering light to activate the IR700, thereby producing an ROS. ## Claims ### Claim 1 A composition comprising: a plurality of nanoparticles, the nanoparticles comprising an 8-arm PEG core; wherein the 8-arm PEG core is substituted with at least a photosensitizer (PS) and a targeting agent (TA) that are directly linked to the 8-arm PEG core; wherein at least three arms of the 8-arm PEG core are unsubstituted; wherein the 8-arm PEG core contains 1-2 PS per 8-arm PEG core; and wherein the 8-arm PEG core has a weight of at least about 40 kDa. ### Claim 2 (depends on 1) The composition of claim 1 wherein the photosensitizer (PS) is IR700. ### Claim 3 (depends on 1) The composition of claim 1 wherein the targeting agent is an RGD peptide. ### Claim 4 (depends on 1) The composition of claim 1 wherein the targeting agent is iRGD. ### Claim 5 (depends on 1) The composition of claim 1 wherein the photosensitizer is IR 700; and wherein the targeting agent is iRGD. ### Claim 6 (depends on 1) The composition of claim 1 wherein the photosensitizer is a phthalocyanine dye; and wherein the targeting agent is a targeting peptide. ### Claim 7 (depends on 1) The composition of claim 1 wherein the direct link is a covalent link. ### Claim 8 (depends on 1) The composition of claim 1 further comprising at least an additive directly linked to the 8-arm PEG core and the additive is selected from the group consisting of therapeutic agents, diagnostic agents, theranostic agents, and combinations thereof. ### Claim 9 (depends on 1) The composition of claim 1 wherein the nanoparticles have a hydrodynamic diameter of 25 nm or less. ### Claim 10 A method of Photodynamic treatment of a medical cardiac, oncologic, bariatric, or dermatologic condition in a subject in need thereof, the method comprising: Administering a composition to the subject, the composition comprising: a plurality of nanoparticles, the nanoparticles comprising an 8-arm PEG core; wherein the 8-arm PEG core is substituted with at least a photosensitizer (PS) and a targeting agent (TA) that are directly linked to the 8-arm PEG core; wherein at least three arms of the 8-arm PEG core are unsubstituted; wherein the 8-arm PEG core contains 1-2 PS; and wherein the 8-arm PEG core has a weight of at least about 40 kDa; Allowing a period of time for the composition to accumulate in a target tissue; and Administering light to activate the PS in the composition; and, Providing sufficient light dosage to kill the target tissue. ### Claim 11 (depends on 10) The Photodynamic treatment method of claim 10 wherein the composition is administered via intravenous injection. ### Claim 12 (depends on 10) The Photodynamic treatment method of claim 10 wherein the light dosage is less that 1KJ/cm2, and wherein the light source is selected from an LED, a continuous laser, a pulsed laser, or combinations thereof. ### Claim 13 (depends on 10) The Photodynamic treatment method of claim 10 wherein the light dosage is between 100 and 400 J/cm2. ### Claim 14 (depends on 10) The Photodynamic treatment method of claim 10 wherein the light is delivered internally to the target tissue via an optical cable. ### Claim 15 (depends on 11) The Photodynamic treatment method of claim 11 wherein the light is delivered externally through the subject's skin. ### Claim 16 (depends on 10) The Photodynamic treatment method of claim 10 wherein the photosensitizer (PS) is a phthalocyanine dye. ### Claim 17 (depends on 10) The Photodynamic treatment method of claim 10 wherein the photosensitizer (PS) is IR700. ### Claim 18 (depends on 1) The composition of claim 1 wherein the photosensitizer (PS) is a phthalocyanine dye. ### Claim 19 (depends on 1) The composition of claim 1, wherein the ratio of TA to PS is 1 to 1 or 2 to 1.